SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 3, 2004
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
| Massachusetts | 0-10824 | 04-2297484 | ||
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
| of incorporation) | Identification Number) |
100 Beaver Street
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant’s telephone number, including area code)
Item 5. Other Events.
On February 3, 2004, Genome Therapeutics (the “Company”) issued a press release announcing that the Securities and Exchange Commission (the “Commission”) declared effective its Registration Statement on Form S-3 (File No. 333-111273) (the “Registration Statement”), which registers the sale of up to 16.8 million shares of its common stock at a per share price of $5.25. The offering is being made in conjunction with the pending merger of the Company and Genesoft Pharmaceuticals. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
| 99.1 | Press Release issued by Genome Therapeutics Corp. on February 3, 2004. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By: /s/ Steven M. Rauscher
Name: Steven M. Rauscher
Title: President and Chief Executive Officer
Date: February 3, 2004
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release issued by Genome Therapeutics Corp. on February 3, 2004. | |